Fujifilm

Fujifilm Diosynth Biotechnologies, established in 2011, is a leading biopharmaceutical contract development and manufacturing organisation (CDMO) with a global footprint. The company is known for its strong commitment to the development and manufacture of large molecules, offering a comprehensive range of services from pre-clinical through to commercial launch and post-market supply. With headquarters in Billingham, UK, Fujifilm Diosynth supports a diverse set of clients, ensuring efficient and reliable biopharmaceutical manufacturing solutions.

The company provides integrated and comprehensive development services, leveraging cutting-edge technology and capabilities across various domains including cell culture, microbial fermentation, and gene therapy. These services are designed to streamline the pathway from research to market, ensuring quality and compliance at every stage. Fujifilm Diosynth's approach is customer-centric, focusing on delivering tailored solutions to meet unique client needs.

Led by CEO Martin Meeson, Fujifilm Diosynth is driven by a mission to advance the development and commercialisation of transformative biopharmaceutical therapies. The team of 72,254 skilled professionals is dedicated to innovation and excellence, enabling the company to maintain its position as an industry leader. Through strategic partnerships and a focus on continuous improvement, Fujifilm Diosynth is committed to shaping the future of biopharmaceutical manufacturing.